61 completed, 16 recruiting, 11 terminated, 5 unknown. 61 Phase 2, 27 Phase 1, 20 Phase 3, 3 Phase 4, 1 Early Phase 1.
Follow Gemtuzumab: new trials by email Literature Review of Gemtuzumab trials Research Report on Gemtuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-20 |
| A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Gemtuzumab, Ziftomenib - Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 22 | 2025-03-07 | 2026-06-12 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-21 |
| Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin - Acute Myeloid Leukemia | Phase 2 | Recruiting | Technische Universität Dresden | 146 | 2024-04-07 | 2026-08-27 |
| Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2023-11-20 | 2026-06-25 |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Azacitidine, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 70 | 2023-07-25 | 2026-09-17 |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Vyxeos, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2023-02-16 | 2026-02-27 |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Fludarabine, Cytarabine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 3 | Recruiting | PedAL BCU, LLC | 130 | 2022-10-01 | 2026-08-24 |
| Vyxeos for Induction of Low- or Intermediate-risk. Vyxeos, Mylotarg - Leukemia, Myeloid, Acute | Phase 2 | Active not recruiting | Shaare Zedek Medical Center | 20 | 2022-08-07 | 2026-10-08 |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS VOR33, Mylotarg - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | Vor Biopharma | 67 | 2021-12-16 | 2025-07-29 |
| Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 1 | 2021-05-21 | 2026-05-20 |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Questionnaire Administration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | Roswell Park Cancer Institute | 24 | 2020-10-23 | 2024-11-01 |
| Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 3 | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 414 | 2020-09-24 | 2024-11-08 |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Technische Universität Dresden | 214 | 2020-09-04 | 2025-09-08 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World Gemtuzumab Ozogamicin - Leukemia, Myeloid, Acute | Completed | Pfizer | 32 | 2020-04-07 | 2021-08-09 | |
| AflacLL1901 (CHOA-AML) Cytarabine, Daunorubicin, Erwinase - Acute Myeloid Leukemia, AML, Childhood | Phase 2 | Terminated | Emory University | 8 | 2020-01-24 | 2022-06-15 |
| Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia Gemtuzumab Ozogamicin (GO), Donor Leukocytes - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Brown University | 11 | 2019-12-31 | 2026-07-23 |
| CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO) - Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent | Phase 2 | Recruiting | University of Maryland, Baltimore | 39 | 2019-11-01 | 2026-07-01 |
Showing 20 of 100. Sign in to see all of them.
Leukemia, Myeloid, Acute (84) · Leukemia (32) · Myelodysplastic Syndromes (20) · Leukemia, Erythroblastic, Acute (14) · Leukemia, Monocytic, Acute (14) · Leukemia, Myelomonocytic, Acute (14) · Congenital Abnormalities (13) · Leukemia, Megakaryoblastic, Acute (13) · Anemia, Refractory, with Excess of Blasts (7) · Leukemia, Promyelocytic, Acute (7) · Recurrence (6) · Leukemia, Basophilic, Acute (5) · Leukemia, Eosinophilic, Acute (5) · Leukemia, Myelomonocytic, Chronic (3) · Leukemia, Myelomonocytic, Juvenile (2)
M.D. Anderson Cancer Center (12) · Wyeth is now a wholly owned subsidiary of Pfizer (6) · Pfizer (5) · Children's Oncology Group (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Fred Hutchinson Cancer Center (4) · National Cancer Institute (NCI) (4) · New York Medical College (3) · SWOG Cancer Research Network (3) · Eastern Cooperative Oncology Group (2) · Jonsson Comprehensive Cancer Center (2) · St. Jude Children's Research Hospital (2) · Technische Universität Dresden (2) · University of Ulm (2) · Versailles Hospital (2)
United States (67) · Germany (12) · Canada (9) · France (9) · Italy (7) · Puerto Rico (7) · Australia (6) · Belgium (6) · Netherlands (6) · Austria (5) · Spain (5) · Switzerland (5) · United Kingdom (5) · Denmark (4) · Israel (4)
Roland Walter (3) · Sergio Amadori, MD (3) · Mark Stanley Berger, MD (2) · Mitchell S Cairo, MD (2) · Richard Aplenc, MD, MSCE (2) · Stephen H. Petersdorf, MD (2) · Alan K. Burnett, MD, FRCP (1) · Alan S. Gamis, MD, MPH (1) · Alexander Ambinder, MD (1) · Alexandra Stevens, MD (1) · Branko Cuglievan (1)
PMID 30062662, PMID 37267439, PMID 36815378, PMID 38295280, PMID 42085603, PMID 15339678, PMID 16730060, PMID 16996130, PMID 18467731, PMID 19776406, PMID 19804455, PMID 20421533, PMID 20451454, PMID 20688393, PMID 21415269, PMID 21504050, PMID 21766293, PMID 22133771, PMID 22649108, PMID 22680764, PMID 22730539, PMID 22855599, PMID 23471307, PMID 23538338, PMID 23591789, PMID 23949430, PMID 24092933, PMID 24127442, PMID 24142996, PMID 24383844, PMID 25092781, PMID 25527568, PMID 25772026, PMID 26755712, PMID 26811524, PMID 27036160, PMID 27133823, PMID 27446991, PMID 28411282, PMID 28883080, PMID 29396857, PMID 31645648, PMID 32330241, PMID 32432489, PMID 32683126, PMID 33080007, PMID 33208914, PMID 33439382, PMID 33843815, PMID 34596937
U10CA032102 (4), 2014 (2), 2017 (1), 2018 (1), 2023 (1), P30CA012197 (1), P30CA015704 (1), P30CA016086 (1), P30CA016672 (1), P30CA043703 (1), R01CA113482 (1), U10CA021115 (1), U10CA031946 (1), U10CA180821 (1), U10CA180886 (1)